Cempra Pharmaceuticals (Nasdaq: CEMP), which went public in Feburary, says it has enough cash for operations through 2014, including funding necessary to support several clinical trials.

The company reported a loss of $25 million, or $47.53 per share, for 2011, in a quarterly financial report issued Friday.

In 2010, the company lost $22.9 million.

Cempra has two lead products in clinical trials. The company launched in 2006.

As of Dec. 31, Cempra reported $15.6 million in cash and equivalents.

The firm raised another $54.7 million through its initial public offering.

It also has a $20 million venture debt facility, $10 million of which was utilized in December.

Read the financial update here.